Nilemdo (Bempedoic Acid)

Bempedoic acid blocks ATP citrate lyase, an enzyme that contributes to cholesterol synthesis in the liver. By inhibiting this step, the drug reduces hepatic cholesterol production, which triggers an increase in LDL‑receptor expression on liver cells, enhancing removal of LDL particles from the blood.

The appropriate dose of Nilemdo is determined by the prescribing healthcare professional based on the patient’s clinical profile and current guidelines. Dosing is individualized, and the prescriber will select the specific strength and frequency that best fits the therapeutic goal.

Safety data for Nilemdo during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and only under the guidance of a qualified healthcare provider.

To order Nilemdo, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nilemdo offers a non‑statin oral option that lowers LDL‑C by targeting cholesterol synthesis upstream of HMG‑CoA reductase. Compared with PCSK9 inhibitors, it is taken orally rather than by injection, but generally provides a more modest LDL‑C reduction. It can be combined with statins, whereas some patients may need alternatives if statins are not tolerated.

Store Nilemdo at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct light, and ensure the container is tightly closed to maintain product stability.

Nilemdo is taken orally, usually as a single tablet once daily. It may be swallowed with or without food, according to the prescriber’s instructions, and should be taken at the same time each day to maintain consistent blood levels.

Serious adverse events include tendon rupture, rhabdomyolysis, severe liver injury, and hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience unexplained muscle pain, dark urine, jaundice, or signs of an allergic reaction.

Nilemdo should be avoided in individuals with known hypersensitivity to bempedoic acid or any excipients, in patients with severe liver disease, and in pregnant women unless the potential benefit justifies the risk. Clinicians should also exercise caution in patients with uncontrolled hyperuricemia or a history of gout.